The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector currently ...

Dec 12 (Reuters) - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

On December 3, BMO Capital’s Evan Seigerman increased the firm’s price target on Amgen Inc. (NASDAQ:AMGN) to $372 from $335 ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Amgen Inc. stock has reached a new 52-week high, hitting $345.95, marking a significant milestone for the biotechnology company. The stock is now trading just 0.99% from its 52-week high of $345.84.

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 ...

The next-generation “GLP-1 plus” drugs will be tailored to the health needs of individual patients.

Ozempic, and the class of weight loss drugs it has come to embody, has left its imprint seemingly everywhere: On the lives of ...

AbbVie, Amgen, and IBM are among 2025’s top dividend performers, each up more than 30% while offering solid yields and steady income.

Amgen is performing well despite some headwinds, and its pipeline is progressing. Gilead Sciences' strong core franchise and diversification efforts should work wonders. Both biotechs have ...

(Reuters) -Amgen on Tuesday reported quarterly financial results that beat Wall Street expectations, and raised its full-year outlook, as 12% sales growth offset expenses related to experimental ...